CD274 and nonpapillary renal cell carcinoma: It has been demonstrated that immune checkpoint inhibitors (ICI) such as nivolumab prolong the overall survival of a subgroup of metastatic ccRCC patients through inhibition of PD-L1-mediated signaling (3).